Skip to content
Facebook Instagram Linkedin

LifeScienceHistory.com

History made daily

  • Home
  • DirectoryExpand
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • CareersExpand
    • Find Your Job
    • Advertise Your Life Science Jobs
  • News and History
  • Cartoons
  • Small World
  • Earth is a RockExpand
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
LifeScienceHistory.com
History made daily
Home / Infectious Disease - Page 28

Infectious Disease

Vaxart reported boosting immune responses in subjects previously vaccinated by a Vaxart vaccine
Biotechnology | Diagnostics | Infectious Disease | Vaccine

Vaxart reported boosting immune responses in subjects previously vaccinated by a Vaxart vaccine

On Jul. 29, 2021, Vaxart announced that it has shown for the first time in clinical trials that…

Read More Vaxart reported boosting immune responses in subjects previously vaccinated by a Vaxart vaccineContinue

Second-generation mRNA COVID-19 vaccine candidate, CV2CoV, demonstrated improved immune response and protection in preclinical study
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Second-generation mRNA COVID-19 vaccine candidate, CV2CoV, demonstrated improved immune response and protection in preclinical study

On Jul. 28, 2021, GlaxoSmithKline and Vir Biotechnology announced they had signed a Joint Procurement Agreement with the…

Read More Second-generation mRNA COVID-19 vaccine candidate, CV2CoV, demonstrated improved immune response and protection in preclinical studyContinue

Oragenics entered into licensing agreement with the NRC of Canada, to pursue next-generation SARS-CoV-2 vaccines
Biotechnology | Infectious Disease | NIH | Vaccine

Oragenics entered into licensing agreement with the NRC of Canada, to pursue next-generation SARS-CoV-2 vaccines

On Jul. 27, 2021, Oragenics announced it had entered into a licensing agreement with the National Research Council…

Read More Oragenics entered into licensing agreement with the NRC of Canada, to pursue next-generation SARS-CoV-2 vaccinesContinue

CHMP adopted positive opinion recommending authorization for use of the Moderna COVID-19 vaccine in adolescents in EU
Biotechnology | COVID-19 | Infectious Disease | Vaccine

CHMP adopted positive opinion recommending authorization for use of the Moderna COVID-19 vaccine in adolescents in EU

On Jul. 23, 2021, Moderna announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…

Read More CHMP adopted positive opinion recommending authorization for use of the Moderna COVID-19 vaccine in adolescents in EUContinue

Moderna announced agreement with Taiwan for 20 million doses of Moderna’s COVID-19 Vaccine and variant booster
Biotechnology | COVID-19 | Infectious Disease | Life Science History | Therapeutics | Vaccine

Moderna announced agreement with Taiwan for 20 million doses of Moderna’s COVID-19 Vaccine and variant booster

On Jul. 22, 2021, Moderna announced a new supply agreement with Taiwan for 20 million doses of Moderna’s…

Read More Moderna announced agreement with Taiwan for 20 million doses of Moderna’s COVID-19 Vaccine and variant boosterContinue

Moderna partnered with Takeda and Government of Japan to aupply additional 50 million doses of COVID-19 vaccine and variant booster candidate
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Moderna partnered with Takeda and Government of Japan to aupply additional 50 million doses of COVID-19 vaccine and variant booster candidate

On Jul. 20, 2021, Moderna announced that the Ministry of Health, Labour and Welfare of Japan (MHLW) and…

Read More Moderna partnered with Takeda and Government of Japan to aupply additional 50 million doses of COVID-19 vaccine and variant booster candidateContinue

CDC and Texas confirmed Monkeypox In U.S. traveler
Biotechnology | CDC | Diagnostics | Infectious Disease | Therapeutics

CDC and Texas confirmed Monkeypox In U.S. traveler

On Jul. 16, 2021, the U.S. Centers for Disease Control and Prevention (CDC) announced and the Texas Department…

Read More CDC and Texas confirmed Monkeypox In U.S. travelerContinue

Moderna announced supply agreement with Argentina for 20 million doses of its COVID-19 vaccine
Biotechnology | COVID-19 | Infectious Disease | Vaccine | WHO

Moderna announced supply agreement with Argentina for 20 million doses of its COVID-19 vaccine

On Jul. 12, 2021, Moderna announced a supply agreement with the government of Argentina for 20 million doses…

Read More Moderna announced supply agreement with Argentina for 20 million doses of its COVID-19 vaccineContinue

Moderna announced Recipharm site in France manufacturing COVID-19 Vaccine following approval by EMA
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Moderna announced Recipharm site in France manufacturing COVID-19 Vaccine following approval by EMA

On Jul. 1, 2021, Moderna confirmed that following the European Medicines Agency’s (EMA) Committee for Human Medicines (CHMP)…

Read More Moderna announced Recipharm site in France manufacturing COVID-19 Vaccine following approval by EMAContinue

Novavax published results of UK phase 3 clinical trial demonstrating high levels of COVID-19 vaccine efficacy
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Novavax published results of UK phase 3 clinical trial demonstrating high levels of COVID-19 vaccine efficacy

On Jun. 30, 2021, Novavax announced the publication of results from the final analysis of a pivotal Phase…

Read More Novavax published results of UK phase 3 clinical trial demonstrating high levels of COVID-19 vaccine efficacyContinue

Paratek announced first BARDA Project BioShield procurement of NUZYRA (omadacycline)
Biotechnology | Infectious Disease | Vaccine

Paratek announced first BARDA Project BioShield procurement of NUZYRA (omadacycline)

On Jun. 29, 2021, Paratek Pharmaceuticals announced it had delivered the first procurement of NUZYRA to the Biomedical…

Read More Paratek announced first BARDA Project BioShield procurement of NUZYRA (omadacycline)Continue

Moderna provides a clinical update on neutralizing activity of COVID-19 vaccine on emerging variants
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Moderna provides a clinical update on neutralizing activity of COVID-19 vaccine on emerging variants

On Jun. 29, 2021, Moderna announced new results from in vitro neutralization studies of sera from individuals vaccinated…

Read More Moderna provides a clinical update on neutralizing activity of COVID-19 vaccine on emerging variantsContinue

Moderna announces Emergency Use Authorization for its COVID-19 vaccine granted by Government of India
Biotechnology | COVID-19 | Infectious Disease | Vaccine | WHO

Moderna announces Emergency Use Authorization for its COVID-19 vaccine granted by Government of India

On Jun. 29, 2021, Moderna announced that the government of India had issued a registration certificate and a…

Read More Moderna announces Emergency Use Authorization for its COVID-19 vaccine granted by Government of IndiaContinue

European Commission purchased additional 150 million doses of Moderna’s COVID-19 vaccine for delivery in 2022
Biotechnology | COVID-19 | Infectious Disease | Vaccine

European Commission purchased additional 150 million doses of Moderna’s COVID-19 vaccine for delivery in 2022

On Jun. 22, 2021, Moderna announced that the European Commission (EC) had purchased an additional 150 million doses…

Read More European Commission purchased additional 150 million doses of Moderna’s COVID-19 vaccine for delivery in 2022Continue

Tonix Pharmaceuticals announced program to develop TNX-102 SL for treatment of long COVID syndrome
Biotechnology | COVID-19 | Infectious Disease | Therapeutics | Vaccine

Tonix Pharmaceuticals announced program to develop TNX-102 SL for treatment of long COVID syndrome

On Jun. 21, 2021, Tonix Pharmaceuticals announced that it planned to develop TNX-102 SL (cyclobenzaprine HCl sublingual tablets)…

Read More Tonix Pharmaceuticals announced program to develop TNX-102 SL for treatment of long COVID syndromeContinue

U.S. Government purchased additional 200 million doses of Moderna’s COVID-19 vaccine
Biotechnology | COVID-19 | Infectious Disease | Vaccine

U.S. Government purchased additional 200 million doses of Moderna’s COVID-19 vaccine

On Jun. 16, 2021, Moderna announced that the U.S. government had purchased an additional 200 million doses of…

Read More U.S. Government purchased additional 200 million doses of Moderna’s COVID-19 vaccineContinue

KPWHRI announced volunteers needed for COVID-19 vaccine-booster trial
Biotechnology | COVID-19 | Infectious Disease | NIH | Vaccine

KPWHRI announced volunteers needed for COVID-19 vaccine-booster trial

On Jun. 16, 2021, Kaiser Permanente Washington Health Research Institute (KPWHRI) announced that was recruiting volunteers in the…

Read More KPWHRI announced volunteers needed for COVID-19 vaccine-booster trialContinue

Moderna and Magenta partner to distribute Moderna’s COVID-19 vaccine in United Arab Emirates
Biotechnology | COVID-19 | Infectious Disease | Therapeutics | Vaccine

Moderna and Magenta partner to distribute Moderna’s COVID-19 vaccine in United Arab Emirates

On Jun. 15, 2021, Moderna and Magenta Investments, an industrial conglomerate in the United Arab Emirates (UAE), announced…

Read More Moderna and Magenta partner to distribute Moderna’s COVID-19 vaccine in United Arab EmiratesContinue

University of British Columbia researchers received the New Frontiers in Research Fund 2020 Exploration award
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Therapeutics | Vaccine

University of British Columbia researchers received the New Frontiers in Research Fund 2020 Exploration award

On Jun. 14, 2021, University of British Columbia researchers Dr. Jayachandran Kizhakkedathu, Dr. Caigan Du and Dr. Christopher…

Read More University of British Columbia researchers received the New Frontiers in Research Fund 2020 Exploration awardContinue

Moderna submitted authorization application for its COVID-19 vaccine in adolescents in Switzerland
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Moderna submitted authorization application for its COVID-19 vaccine in adolescents in Switzerland

On Jun. 14, 2021, Moderna announced that it had submitted an authorization application to Swissmedic for use of…

Read More Moderna submitted authorization application for its COVID-19 vaccine in adolescents in SwitzerlandContinue

Novavax COVID-19 vaccine demonstrated 90% overall efficacy and 100% protection in phase 3 trial
Biotechnology | COVID-19 | Infectious Disease | Nanotechnology | Vaccine

Novavax COVID-19 vaccine demonstrated 90% overall efficacy and 100% protection in phase 3 trial

On Jun. 14, 2021, Novavax announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against…

Read More Novavax COVID-19 vaccine demonstrated 90% overall efficacy and 100% protection in phase 3 trialContinue

Novavax announced positive results from study of influenza vaccine and COVID-19 vaccine candidate administered simultaneously
Biotechnology | Infectious Disease | Influenza | Vaccine

Novavax announced positive results from study of influenza vaccine and COVID-19 vaccine candidate administered simultaneously

On Jun. 14, 2021, Novavax announced data from the first co-administration study of a SARS-CoV-2 vaccine candidate [Novavax,…

Read More Novavax announced positive results from study of influenza vaccine and COVID-19 vaccine candidate administered simultaneouslyContinue

Novavax announces positive data from three complementary studies of COVID-19 Beta variant strain vaccine
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Novavax announces positive data from three complementary studies of COVID-19 Beta variant strain vaccine

On Jun. 11, 2021, Novavax announced preclinical and clinical data on the company’s original recombinant protein COVID-19 vaccine…

Read More Novavax announces positive data from three complementary studies of COVID-19 Beta variant strain vaccineContinue

Moderna filed for Emergency Use Authorization for its COVID-19 vaccine in adolescents in the United States
Biotechnology | COVID-19 | FDA | Infectious Disease | Vaccine

Moderna filed for Emergency Use Authorization for its COVID-19 vaccine in adolescents in the United States

On Jun. 10, 2021, Moderna announced that it had requested an emergency use authorization (EUA) for its COVID-19…

Read More Moderna filed for Emergency Use Authorization for its COVID-19 vaccine in adolescents in the United StatesContinue

RECOVERY trial found aspirin does not improve survival for patients hospitalised with COVID-19
Biotechnology | COVID-19 | Diagnostics | FDA | Infectious Disease | Neurology | Pharmaceutical

RECOVERY trial found aspirin does not improve survival for patients hospitalised with COVID-19

On Jun. 8, 2021, the University of Oxford announced that the RECOVERY trial found aspirin does not improve…

Read More RECOVERY trial found aspirin does not improve survival for patients hospitalised with COVID-19Continue

Senolytics reduced COVID-19 symptoms in preclinical studies
Biotechnology | COVID-19 | Infectious Disease | Therapeutics | Veterinary

Senolytics reduced COVID-19 symptoms in preclinical studies

On Jun. 8, 2021, Mayo Clinic researchers and colleagues at the University of Minnesota showed that COVID-19 exacerbates…

Read More Senolytics reduced COVID-19 symptoms in preclinical studiesContinue

INOVIO expanded partnership with Advaccine to conduct global phase 3 efficacy trial of COVID-19 DNA vaccine candidate
Biotechnology | COVID-19 | Infectious Disease | Vaccine

INOVIO expanded partnership with Advaccine to conduct global phase 3 efficacy trial of COVID-19 DNA vaccine candidate

On Jun. 8, 2021, Inovio Pharma announced an expansion of its previously announced partnership with Advaccine Biopharmaceuticals to…

Read More INOVIO expanded partnership with Advaccine to conduct global phase 3 efficacy trial of COVID-19 DNA vaccine candidateContinue

MediciNova initiated sheep study under BARDA to develop MN-166 (ibudilast) as countermeasure against chlorine
Biotechnology | Chemical | Infectious Disease | Therapeutics

MediciNova initiated sheep study under BARDA to develop MN-166 (ibudilast) as countermeasure against chlorine

On Jun. 7, 2021, MediciNova announced it had initiated a sheep study to investigate MN-166 (ibudilast) in an…

Read More MediciNova initiated sheep study under BARDA to develop MN-166 (ibudilast) as countermeasure against chlorineContinue

Moderna filed for conditional Marketing Approval for its COVID-19 vaccine in adolescents in the EU
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Moderna filed for conditional Marketing Approval for its COVID-19 vaccine in adolescents in the EU

On Jun. 7, 2021, Moderna announced that it had submitted for a conditional marketing approval (CMA) for its…

Read More Moderna filed for conditional Marketing Approval for its COVID-19 vaccine in adolescents in the EUContinue

Moderna and Medison Pharma partnered to commercialize COVID-19 vaccine in Central Eastern Europe and Israel
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Moderna and Medison Pharma partnered to commercialize COVID-19 vaccine in Central Eastern Europe and Israel

On Jun. 7, 2021, Moderna announced a new agreement to commercialize its COVID-19 Vaccine across Central Eastern Europe…

Read More Moderna and Medison Pharma partnered to commercialize COVID-19 vaccine in Central Eastern Europe and IsraelContinue

Page navigation

Previous PagePrevious 1 … 26 27 28 29 30 … 63 Next PageNext
  • Categories
  • Timeline
  • Agriculture
  • Artificial Intelligence
  • Biology
  • Biotechnology
  • Cartoons – Historical
  • Cartoons – Original
  • CDC
  • CDMO
  • Chemical
  • Clinical Research
  • Cloning
  • CMO
  • COVID-19
  • CRISPR
  • CRO
  • Cryogenic
  • Dentistry
  • Diagnostics
  • Disease
  • Energy
  • Environmental
  • EPA
  • FDA
  • Forestry
  • Genomics
  • HIV
  • Infectious Disease
  • Influenza
  • IRB
  • Life Science History
  • Marine Science
  • Materials
  • Measles
  • Medical Device
  • Medicine
  • Nanotechnology
  • Neurology
  • NIH
  • Non-Profit Research
  • Nutraceuticals
  • Oncology
  • Ophthalmogy
  • Organ Transplant
  • Orthopedic
  • Other
  • Pharmaceutical
  • Plague
  • Polio
  • Prehistory
  • Radiology
  • Rare Disease
  • Stem Cell
  • Therapeutics
  • U.S. Congress
  • Uncategorized
  • USDA
  • Vaccine
  • Veterinary
  • WHO
  • Women's Health
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004
  • 2003
  • 2002
  • 2001
  • 2000
  • 1999
  • 1998
  • 1997
  • 1996
  • 1995
  • 1994
  • 1993
  • 1992
  • 1991
  • 1990
  • 1989
  • 1988
  • 1987
  • 1986
  • 1985
  • 1984
  • 1983
  • 1982
  • 1981
  • 1980
  • 1979
  • 1978
  • 1977
  • 1976
  • 1975
  • 1974
  • 1973
  • 1972
  • 1971
  • 1970
  • 1969
  • 1968
  • 1967
  • 1966
  • 1965
  • 1964
  • 1963
  • 1962
  • 1961
  • 1960
  • 1959
  • 1958
  • 1957
  • 1956
  • 1955
  • 1954
  • 1953
  • 1952
  • 1951
  • 1950
  • 1949
  • 1948
  • 1947
  • 1946
  • 1945
  • 1944
  • 1943
  • 1942
  • 1941
  • 1940
  • 1939
  • 1938
  • 1937
  • 1936
  • 1935
  • 1934
  • 1933
  • 1932
  • 1931
  • 1930
  • 1929
  • 1928
  • 1927
  • 1926
  • 1925
  • 1924
  • 1923
  • 1922
  • 1921
  • 1920
  • 1919
  • 1918
  • 1917
  • 1916
  • 1915
  • 1914
  • 1913
  • 1912
  • 1911
  • 1910
  • 1909
  • 1908
  • 1907
  • 1906
  • 1905
  • 1904
  • 1903
  • 1902
  • 1901
  • 1900
  • 1899
  • 1898
  • 1897
  • 1896
  • 1895
  • 1894
  • 1893
  • 1892
  • 1891
  • 1890
  • 1889
  • 1888
  • 1887
  • 1886
  • 1885
  • 1884
  • 1883
  • 1882
  • 1881
  • 1880
  • 1879
  • 1878
  • 1877
  • 1876
  • 1875
  • 1874
  • 1873
  • 1872
  • 1871
  • 1870
  • 1869
  • 1868
  • 1867
  • 1866
  • 1865
  • 1864
  • 1863
  • 1862
  • 1861
  • 1860
  • 1859
  • 1858
  • 1857
  • 1856
  • 1855
  • 1854
  • 1853
  • 1852
  • 1851
  • 1850
  • 1849
  • 1848
  • 1847
  • 1846
  • 1845
  • 1844
  • 1843
  • 1842
  • 1840
  • 1839
  • 1838
  • 1837
  • 1836
  • 1834
  • 1833
  • 1832
  • 1831
  • 1830
  • 1828
  • 1827
  • 1826
  • 1825
  • 1824
  • 1823
  • 1820
  • 1819
  • 1818
  • 1817
  • 1816
  • 1813
  • 1811
  • 1810
  • 1809
  • 1808
  • 1804
  • 1802
  • 1801
  • 1800
  • 1799
  • 1798
  • 1796
  • 1795
  • 1794
  • 1793
  • 1790
  • 1789
  • 1788
  • 1786
  • 1785
  • 1784
  • 1782
  • 1781
  • 1777
  • 1769
  • 1765
  • 1761
  • 1753
  • 1751
  • 1749
  • 1747
  • 1746
  • 1743
  • 1741
  • 1738
  • 1727
  • 1723
  • 1721
  • 1720
  • 1718
  • 1716
  • 1712
  • 1697
  • 1693
  • 1683
  • 1674
  • 1667
  • 1666
  • 1665
  • 1664
  • 1663
  • 1658
  • 1656
  • 1647
  • 1636
  • 1634
  • 1629
  • 1621
  • 1603
  • 1580
  • 1521
  • 1510
  • 1403
  • 1377
  • 1370
  • 1363
  • 1348
  • 1346
  • 1322
  • 1285
  • 1202
  • 1200
  • 1179
  • 1100
  • 1050
  • 541
  • 470
  • 1
Subscribe to E-History

Subscribe

* indicates required

LifeScienceHistory.com

LifeScienceHistory.com Where history is made daily, is a comprehensive companion of life science. Simply put, we dig history and we mine data.

More

  • About
  • Life Science Heroes

Advertising

  • Life Science Banner Advertising
  • Advertise Your Life Science Jobs

Legal

  • Privacy Policy
  • Terms of Use

© 2025 LifeScienceHistory.com by James Web Design

Facebook Instagram Linkedin
  • Home
  • Directory
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • Careers
    • Find Your Job
    • Advertise Your Life Science Jobs
  • News and History
  • Cartoons
  • Small World
  • Earth is a Rock
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
Search